Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
NeoGenomics validates and launches series of NeoTYPE cancer profiling tests

NeoGenomics validates and launches series of NeoTYPE cancer profiling tests

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

TCGA Research Network identify new potential therapeutic targets for major form of bladder cancer

TCGA Research Network identify new potential therapeutic targets for major form of bladder cancer

High doses of 4-MEI in carbonated beverages may result in higher incidence of leukemia, says study

High doses of 4-MEI in carbonated beverages may result in higher incidence of leukemia, says study

Scientists develop monoclonal antibodies that may lead to new, innovative treatments for cancer patients

Scientists develop monoclonal antibodies that may lead to new, innovative treatments for cancer patients

Transgenic mouse model validates mutant IDH2 protein as candidate for targeted anticancer therapies

Transgenic mouse model validates mutant IDH2 protein as candidate for targeted anticancer therapies

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

FDA approves Miltenyi Biotec's CliniMACS CD34 Reagent System for prevention of GVHD

FDA approves Miltenyi Biotec's CliniMACS CD34 Reagent System for prevention of GVHD

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

NCCC physicians use new gene sequencing equipment for testing abnormal DNA in cancerous tumor cells

NCCC physicians use new gene sequencing equipment for testing abnormal DNA in cancerous tumor cells

New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma

New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

Cost of care, diabetes are top Latino health concerns

Cost of care, diabetes are top Latino health concerns

Mutation in bone cells may cause acute myeloid leukemia: Study

Mutation in bone cells may cause acute myeloid leukemia: Study

Damon Runyon Cancer Research Foundation awards $2.25M to six innovative young scientists

Damon Runyon Cancer Research Foundation awards $2.25M to six innovative young scientists

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

First Edition: January 21, 2014

First Edition: January 21, 2014

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.